Evidence map›Paper›PMID 37496609›Full record

ArticleOpen forum infectious diseases2023

Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru.

Rifat S Rahman, Marco A Tovar, Jesús Peinado, J Santiago Palomino, Claudio Ramirez, Fernando Llanos-Zavalaga, Ernesto Peralta, Gissela Valderrama, Lourdes B Ramos Cordova, Lucero I Sanchez Cortez and 6 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Rifat S RahmanHarvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-3331-9312
Marco A TovarSocios En Salud Sucursal Peru, Lima, Peru.
Jesús PeinadoSocios En Salud Sucursal Peru, Lima, Peru.
J Santiago PalominoSocios En Salud Sucursal Peru, Lima, Peru.
Claudio RamirezDirección de Redes Integradas de Salud-Lima Norte, Lima, Peru.
Fernando Llanos-ZavalagaDirección de Redes Integradas de Salud-Lima Norte, Lima, Peru.
Ernesto PeraltaDirección de Redes Integradas de Salud-Lima Norte, Lima, Peru.
Gissela ValderramaSocios En Salud Sucursal Peru, Lima, Peru.
Lourdes B Ramos CordovaSocios En Salud Sucursal Peru, Lima, Peru.
Lucero I Sanchez CortezSocios En Salud Sucursal Peru, Lima, Peru.
German RodriguezGRV Especialistas Clínicos SAC, Lima, Peru.
Allison N LaHoodDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Molly F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Carole D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leonid LeccaSocios En Salud Sucursal Peru, Lima, Peru.
Gustavo E VelásquezDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-1438-0692
EsSALUD · PEHarvard University · USBrigham and Women's Hospital · USCentro Peruano de Estudios Sociales · PEPeruvian University of Applied Sciences · PEUniversidad Peruana Cayetano Heredia · PE

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Safety and tolerability of new and repurposed drugs for MDR-TB treatmentK08AI141740 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VELASQUEZ, GUSTAVO EDUARDO · 2019 to 2023
$985k
NIAID NIH HHS K08 AI141740NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

Background: Few studies have examined the burden of postacute sequelae of coronavirus disease 2019 (COVID-19) (PASC) in low- and middle-income countries. We sought to characterize PASC with self-reported questionnaires and clinical examinations of end-organ function in Lima, Peru. Methods: From January to July 2021, we recruited participants at least 8 weeks after COVID-19 diagnosis from a case registry in Lima, Peru. We evaluated participants for PASC with questionnaires, neuropsychiatric evaluations, chest X-ray, spirometry, electrocardiogram, and echocardiogram. We used multivariable models to identify risk factors for PASC. Results: We assessed 989 participants for PASC at a median 4.7 months after diagnosis. Clinically significant respiratory symptoms were reported by 68.3% of participants, particularly those who had been severely ill during acute COVID-19, and were associated with cardiac findings of ventricular hypertrophy or dilation on echocardiogram. Neuropsychiatric questionnaires were consistent with depression in 20.7% and cognitive impairment in 8.0%. Female sex and older age were associated with increased risk of respiratory (adjusted odds ratio [aOR], 2.36 [95% confidence interval {CI}, 1.69-3.31] and aOR, 1.01 [95% CI, 1.00-1.03], respectively) and neuropsychiatric sequelae (aOR, 2.99 [95% CI, 2.16-4.18] and aOR, 1.02 [95% CI, 1.01-1.03], respectively). Conclusions: COVID-19 survivors in Lima, Peru, experienced frequent postacute respiratory symptoms and depression, particularly among older and female participants. Clinical examinations highlighted the need for cardiopulmonary rehabilitation among persons with severe COVID-19; psychosocial support may be required among all COVID-19 survivors.

Indexed as

COVID-19PerupostacuteSARS-CoV-2sequelae

Identifiers

PMID37496609
PMCPMC10368202
OpenAlexW4382465758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.